Gut-microbiota-metabolite axis in early renal function decline

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Barrios, Clara ^a,b   Beaumont, Michelle ^a   Pallister, Tess ^a   Villar, Judith ^b   Goodrich, Julia K ^c   Clark, Andrew ^c   Pascual, Julio ^b   Ley, Ruth E ^c   Spector, Tim D ^a   Bell, Jordana T ^a   Menni, Cristina ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HOSPITAL DEL MAR   (Spain)

^c Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTAMINE DERIVATIVE; INDICAN; PARA CRESYL SULFATE; PHENOL DERIVATIVE; PHENYLACETYLGLUTAMINE; UNCLASSIFIED DRUG; 4-CRESOL SULFATE; CRESOL; GLUTAMINE; SULFATE;

ADULT; AGED; ARTICLE; BACTERIUM IDENTIFICATION; BODY MASS; CHRISTENSENELLACEAE; CLOSTRIDIALES; COHORT ANALYSIS; FAMILY ASSESSMENT; FEMALE; GLOMERULUS FILTRATION RATE; GRAM POSITIVE BACTERIUM; HUMAN; INTESTINE FLORA; KIDNEY FUNCTION; LACHNOSPIRACEAE; MALE; NONHUMAN; POPULATION RESEARCH; RUMINOCOCCACEAE; VERY ELDERLY; ANALOGS AND DERIVATIVES; BLOOD; CLASSIFICATION; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; FECES; FERMENTATION; GENETICS; ISOLATION AND PURIFICATION; KIDNEY DISEASE; METABOLISM; METABOLOME; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; RIBOTYPING; TWINS;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CLOSTRIDIALES; CRESOLS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASES IN TWINS; FECES; FEMALE; FERMENTATION; GASTROINTESTINAL MICROBIOME; GLOMERULAR FILTRATION RATE; GLUTAMINE; HUMANS; INDICAN; KIDNEY DISEASES; MALE; METABOLOME; MICROBIOTA; MIDDLE AGED; RIBOTYPING; SULFURIC ACID ESTERS;

EID: 84942288138     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134311     Document Type: Article

References (38)

1. Han JL, Lin HL. Intestinal microbiota and type 2 diabetes: From mechanism insights to therapeutic perspective. World journal of gastroenterology: WJG, 20: 17737-17745, 2014.
2. Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and metabolic syndrome. World journal of gastroenterology: WJG, 20: 16079-16094, 2014.
3. Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B. Metabolite profiling of fecal water extracts from human colorectal cancer. NMR in biomedicine, 22: 342-348, 2009.
4. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature, 513: 59-64, 2014.
5. Viaene L, Thijs L, Jin Y, Liu Y, Gu Y, Meijers B, et al. Heritability and clinical determinants of serum indoxyl sulfate and p-cresyl sulfate, candidate biomarkers of the human microbiome enterotype. PloS one, 9: e79682, 2014.
6. Shin SY, Fauman EB, Petersen AK, Krumsiek J, Santos R, Huang J, et al. An atlas of genetic influences on human blood metabolites. Nature genetics, 46: 543-550, 2014.
7. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell, 134: 714-717, 2008.
8. Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney international, 83: 1010-1016, 2013.
9. Vaziri ND. CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity. Current opinion in nephrology and hypertension, 21: 587-592, 2012.
10. Meyer TW, Hostetter TH. Uremic solutes from colon microbes. Kidney international, 81: 949-954, 2012.
11. Niwa T. Indoxyl sulfate is a nephro-vascular toxin. Journal of renal nutrition: the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 20: S2-6, 2010.
12. Tumur Z, Shimizu H, Enomoto A, Miyazaki H, Niwa T. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. American journal of nephrology, 31: 435-441, 2010.
13. Poesen R, Viaene L, Verbeke K, Augustijns P, Bammens B, Claes K, et al. Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease. BMC nephrology, 15: 87, 2014.
14. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al. European Uremic Toxin Work, G: Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clinical journal of the American Society of Nephrology: CJASN, 4: 1551-1558, 2009.
15. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 26: 938-947, 2011.
16. Menni C, Mangino M, Cecelja M, Psatha M, Brosnan MJ, Trimmer J, et al. Metabolomic study of carotid-femoral pulse-wave velocity in women. Journal of hypertension, 33: 791-796, 2015.
17. Cruickshank-Quinn CI, Mahaffey S, Justice MJ, Hughes G, Armstrong M, Bowler RP, et al. Transient and persistent metabolomic changes in plasma following chronic cigarette smoke exposure in a mouse model. PloS one, 9: e101855, 2014.
18. Kang SM, Park JC, Shin MJ, Lee H, Oh J, Ryu do H, et al. (1)H nuclear magnetic resonance based metabolic urinary profiling of patients with ischemic heart failure. Clinical biochemistry, 44: 293-299, 2011.
19. Niewczas MA, Sirich TL, Mathew AV, Skupien J, Mohney RP, Warram JH, et al. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney international, 85: 1214-1224, 2014.
20. Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clinical journal of the American Society of Nephrology: CJASN, 5: 1182-1189, 2010.
21. Lin CJ, Chen HH, Pan CF, Chuang CK, Wang TJ, Sun FJ, et al. p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. Journal of clinical laboratory analysis, 25: 191-197, 2011.
22. Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. Journal of the American Society of Nephrology: JASN, 25: 657-670, 2014.
23. Aronov PA, Luo FJ, Plummer NS, Quan Z, Holmes S, Hostetter TH, et al. Colonic contribution to uremic solutes. Journal of the American Society of Nephrology: JASN, 22: 1769-1776, 2011.
24. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, et al. Chronic kidney disease alters intestinal microbial flora. Kidney international, 83: 308-315, 2013.
25. Teucher B, Skinner J, Skidmore PM, Cassidy A, Fairweather-Tait SJ, Hooper L, et al. Dietary patterns and heritability of food choice in a UK female twin cohort. Twin research and human genetics: the official journal of the International Society for Twin Studies, 10: 734-748, 2007.
26. Menni C, Zhai G, Macgregor A, Prehn C, Romisch-Margl W, Suhre K, et al. Targeted metabolomics profiles are strongly correlated with nutritional patterns in women. Metabolomics: Official journal of the Metabolomic Society, 9: 506-514, 2013.
27. Meijers BK, Bammens B, Verbeke K, Evenepoel P, A review of albumin binding in CKD. American journal of kidney diseases: the official journal of the National Kidney Foundation, 51: 839-850, 2008.
28. Poesen R, Viaene L, Verbeke K, Claes K, Bammens B, Sprangers B, et al. Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD. Clinical journal of the American Society of Nephrology: CJASN, 8: 1508-1514, 2013.
29. Goodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, et al. Human genetics shape the gut microbiome. Cell, 159: 789-799, 2014.
30. Angelakis E, Merhej V, Raoult D. Related actions of probiotics and antibiotics on gut microbiota and weight modification. The Lancet Infectious diseases, 13: 889-899, 2013.
31. Vital M, Howe AC, Tiedje JM. Revealing the bacterial butyrate synthesis pathways by analyzing (meta) genomic data. mBio, 5: e00889, 2014.
32. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology, 146: 1489-1499, 2014.
33. Ranganathan N, Friedman EA, Tam P, Rao V, Ranganathan P, Dheer R. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Current medical research and opinion, 25: 1919-1930, 2009.
34. Moayyeri A, Hammond CJ, Valdes AM, Spector TD. Cohort Profile: TwinsUK and healthy ageing twin study. International journal of epidemiology, 42: 76-85, 2013.
35. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. Ckd, EPI: A new equation to estimate glomerular filtration rate. Annals of internal medicine, 150: 604-612, 2009.
36. Menni C, Kastenmuller G, Petersen AK, Bell JT, Psatha M, Tsai PC, et al. Metabolomic markers reveal novel pathways of ageing and early development in human populations. International journal of epidemiology, 42: 1111-1119, 2013.
37. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Analytical chemistry, 81: 6656-6667, 2009.
38. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. Nature methods, 7: 335-336, 2010.